Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma

This study has been completed.
Astellas Pharma Europe B.V.
Information provided by:
Astellas Pharma Inc Identifier:
First received: September 12, 2005
Last updated: April 15, 2008
Last verified: April 2008
This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.

Condition Intervention Phase
Asthma, Bronchial
Bronchial Asthma
Drug: Tacrolimus
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Enrollment: 160
Study Completion Date: July 2005
Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of asthma
  • Patients treated with inhaled corticosteroid and long acting beta 2 agonist
  • FEV1(forced expiratory volume in 1 second)>50% to 80%

Exclusion Criteria:

  • Respiratory infection within 2weeks
  • Asthma exacerbation within 6 weeks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00189722

Czech Republic
Brno, Czech Republic, 65691
Krhanice, Czech Republic, 25742
Olomouc, Czech Republic, 77520
Sumperk, Czech Republic, 78752
Berlin, Germany, 10365
Berlin, Germany, 10717
Berlin, Germany, 14050
Deggendort, Germany, 94469
Hamburg, Germany, 20535
Hannover, Germany, 30159
Munchen, Germany, 80802
Rudersdorf, Germany, 15562
Wiesbaden, Germany, 65187
Bialystok, Poland, 15-025
Krakow, Poland, 31-133
Lodz, Poland, 90-153
Lublin, Poland, 20-718
Tarnow, Poland, 33-100
Wroclaw, Poland, 50-434
Russian Federation
Ekaterinburg, Russian Federation, 620142
Moscow, Russian Federation, 143420
Smolensk, Russian Federation, 214018
St. Petersburg, Russian Federation, 194291
St. Petersburg, Russian Federation, 197022
St. Petersburg, Russian Federation, 197291
Dnepropetrovsk, Ukraine, 49044
Kiev, Ukraine, 03680
Zaporozhye, Ukraine, 69035
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma Europe B.V.
Study Director: R. G. M. vom Amsterdam, MD Astellas Pharma Europe B.V.
  More Information Identifier: NCT00189722     History of Changes
Other Study ID Numbers: FG-506-17-05
Study First Received: September 12, 2005
Last Updated: April 15, 2008

Keywords provided by Astellas Pharma Inc:
Anti-asthmatic drug
Administration, inhalation

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017